Correlation of BRAFV600E mutation and glucose metabolism in thyroid cancer patients: An 18F-FDG PET study Journal Article
| Authors: | Nagarajah, J.; Ho, A. L.; Tuttle, R. M.; Weber, W. A.; Grewal, R. K. |
| Article Title: | Correlation of BRAFV600E mutation and glucose metabolism in thyroid cancer patients: An 18F-FDG PET study |
| Abstract: | There is significant interest in a better understanding of the genetic underpinnings of the increased glucose metabolic rates of cancer cells. Thyroid cancer demonstrates a broad variability of 18F-FDG uptake as well as several well-characterized oncogenic mutations. In this study, we evaluated the differences in glucose metabolism of the BRAFV600E mutation versus BRAF wild-type (BRAF-WT) in patients with metastatic differentiated thyroid cancer (DTC) and poorly differentiated thyroid cancer (PDTC). Methods: Forty-eight DTC and 34 PDTC patients who underwent 18F-FDG PET/CT for tumor staging were identified from a database search. All patients were tested for the BRAFV600E mutation and assigned to 1 of 2 groups: BRAFV600E mutated and BRAF-WT. 18F-FDG uptake of tumor tissue was quantified by maximum standardized uptake value (SUV<inf>max</inf>) of the hottest malignant lesion in 6 prespecified body regions (thyroid bed, lymph nodes, lung, bone, soft tissue, and other). When there were multiple lesions in 1 of the prespecified body regions, only the 1 with the highest 18F-FDG uptake was analyzed. Results: In the DTC cohort, 24 tumors harbored a BRAFV600E mutation, whereas 24 tumors were BRAF-WT. 18F-FDG uptake of BRAFV600E-positive lesions (median SUV<inf>max</inf> ,6.3; n = 53) was significantly higher than that of BRAF-WT lesions (n = 39; median SUV<inf>max</inf> , 4.7; P = 0.019). In the PDTC group, only 5 tumors were BRAFV600E -positive, and their 18F-FDG uptake was not significantly different from the BRAF-WT tumors. There was also no significant difference between the SUV<inf>max</inf> of all DTCs and PDTCs, regardless of BRAF mutational status (P = 0.90). Conclusion: These data suggest that BRAFV600E-mutated DTCs are significantly more 18F-FDG-avid than BRAF-WT tumors. The effect of BRAFV600E on tumor glucose metabolism in PDTC needs further study in larger groups of patients. COPYRIGHT © 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
| Keywords: | adult; controlled study; bone tumor; gene mutation; major clinical study; cancer staging; positron emission tomography; tumor localization; wild type; lung tumor; lymphoma; fluorodeoxyglucose f 18; glucose; thyroid cancer; b raf kinase; soft tissue tumor; correlational study; braf gene; glucose metabolism; differentiated thyroid cancer; poorly differentiated thyroid cancer; human; male; female; priority journal; article; 18f-fdg uptake; brafv600e-mutation; dtc; pdtc |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 56 |
| Issue: | 5 |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2015-05-01 |
| Start Page: | 662 |
| End Page: | 667 |
| Language: | English |
| DOI: | 10.2967/jnumed.114.150607 |
| PROVIDER: | scopus |
| PUBMED: | 25814520 |
| PMCID: | PMC4970467 |
| DOI/URL: | |
| Notes: | Export Date: 3 June 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work